10-Q: Geron Q3 2025: RYTELO Sales Surge, Key Trial Fully Enrolled

Geron Corporation reported a significant increase in RYTELO product revenue for Q3 2025 and announced full enrollment in its pivotal Phase 3 IMpactMF clinical trial.

Summary

• Product revenue, net, for the three months ended September 30, 2025, was $47.2 million, a 67% increase from $28.2 million in the same period of 2024.
• Total revenues for the nine months ended September 30, 2025, reached $135.9 million, a 361% increase from $29.5 million in the prior year period.
• The net loss for Q3 2025 improved to $18.4 million, down from $26.4 million in Q3 2024, and for the nine months, net loss improved to $54.6 million from $149.2 million.
• Cash, cash equivalents, restricted cash, and marketable securities totaled $421.5 million as of September 30, 2025, a decrease from $502.9 million at December 31, 2024.
• The Phase 3 IMpactMF clinical trial for relapsed/refractory myelofibrosis reached full enrollment by the end of September 2025.
• Geron received marketing authorization for RYTELO in the European Union in March 2025 and plans for commercialization in select EU markets in 2026 through third-party partners.
• A material weakness in internal control over financial reporting related to Information Technology General Controls (ITGCs) was identified and remains unremediated as of September 30, 2025, with remediation efforts planned for completion by the end of Q4 2025.
• The company is facing securities class action and derivative lawsuits alleging false and misleading statements concerning RYTELO's commercial potential.

Sentiment

Score: 6

Explanation: The strong initial commercial performance of RYTELO and the full enrollment of a pivotal Phase 3 trial are significant positives. However, persistent net losses, increased debt service obligations, and the overhang of securities litigation, coupled with an identified material weakness in internal controls, temper the overall sentiment. The company is making progress but faces substantial financial and operational challenges.

Positives

• Product revenue, net, for RYTELO increased by 67% to $47.2 million in Q3 2025 compared to Q3 2024, demonstrating strong commercial traction for the newly launched product.
• Total revenues for the nine months ended September 30, 2025, grew by 361% to $135.9 million, reflecting the successful U.S. commercial launch of RYTELO in June 2024.
• Net loss significantly improved by 30% in Q3 2025 and 63% for the nine months ended September 30, 2025, indicating progress towards profitability.
• The Phase 3 IMpactMF clinical trial for relapsed/refractory myelofibrosis achieved full enrollment by the end of September 2025, a key milestone for pipeline advancement.
• RYTELO received marketing authorization from the European Commission in March 2025, opening up future commercial opportunities in select EU markets.
• Loss from operations improved by 51% in Q3 2025 and 72% for the nine months ended September 30, 2025, reflecting better operational efficiency relative to revenue growth.

Negatives

• The company continues to incur significant net losses, with an accumulated deficit of approximately $1.8 billion as of September 30, 2025.
• Cash, cash equivalents, restricted cash, and marketable securities decreased to $421.5 million from $502.9 million at December 31, 2024, indicating ongoing cash burn.
• Interest expense increased significantly by 184% in Q3 2025 and 159% for the nine months ended September 30, 2025, primarily due to the Pharmakon Loan Agreement and Royalty Pharma Agreement.
• RYTELO sales trends have shown variability, with Q3 2025 net product revenue of $47.2 million being slightly lower than Q2 2025's $49.0 million.
• A material weakness in internal control over financial reporting related to ITGCs was identified and remains unremediated, posing a risk of material misstatements.
• The company is a defendant in multiple securities class action and derivative lawsuits, which could result in substantial damages and divert management's attention and resources.

Risks

• The near-term prospects are wholly dependent on RYTELO, and limited commercialization experience may lead to unsuccessful or less successful sales, marketing, and distribution.
• Failure to maintain acceptable prices or adequate reimbursement for RYTELO from third-party payors could severely limit its use and market acceptance.
• The healthcare community may be slow to adopt or unreceptive to RYTELO, especially in new patient segments, limiting growth potential.
• Market opportunities for RYTELO may be smaller than estimated, adversely affecting revenue and business.
• Competitors may develop superior or more cost-effective products, significantly impacting RYTELO's commercial viability.
• Reliance on a select network of third-party distributors and specialty pharmacies for RYTELO distribution poses risks if these parties fail to perform.
• Inability to maintain regulatory approvals for RYTELO in the U.S. and EU, or comply with post-marketing requirements, could lead to penalties or product withdrawal.
• RYTELO may cause undesirable or unintended side effects or adverse events, potentially halting commercialization or delaying regulatory approval for new indications.
• Results from prior non-clinical studies and clinical trials may not predict success in later trials, such as IMpactMF, leading to potential failures or delays.
• Failure to maintain a manufacturing supply chain or reliance on single-source third-party manufacturers could interrupt or limit RYTELO supply.
• The company has a history of net losses and may not achieve consistent future profitability.
• Operating results are unpredictable and may fluctuate, potentially causing stock price declines if expectations are not met.
• Failure to obtain additional capital, if and when needed, would force delays or abandonment of RYTELO development or commercialization.
• Inability to obtain and maintain sufficient intellectual property protection and regulatory exclusivities for RYTELO could allow competitors to commercialize similar products.
• Involvement in lawsuits to protect or enforce intellectual property rights can be expensive, time-consuming, and unsuccessful.
• Changes in U.S. or international patent law or interpretations could diminish the value of patents.
• Patent terms may be inadequate to protect RYTELO's competitive position for a sufficient amount of time.
• The company may be subject to infringement claims that are costly to defend and could limit its ability to use disputed technologies.
• Inability to successfully retain or recruit key personnel could impair commercialization and development efforts.
• Management transition creates uncertainties and could harm the business.
• Inability to establish future collaborative arrangements for RYTELO on acceptable terms could delay or abandon commercialization or further development.
• Operating through subsidiaries in the UK and Netherlands exposes the company to additional costs and risks associated with international business.
• Inability to obtain or maintain sufficient insurance against potential liabilities could have a material adverse effect.
• Employees, contractors, or vendors may engage in misconduct or improper activities, leading to regulatory sanctions or reputational harm.
• Business could be negatively impacted by environmental, social, and corporate governance (ESG) matters or reporting failures.
• Failure to maintain effective internal controls in accordance with Section 404 of the Sarbanes-Oxley Act could have a material adverse effect.
• Changes in tax laws or regulations could adversely affect the business.
• Ability to use net operating loss carryforwards and certain other tax attributes may be limited.

Future Outlook

The company anticipates increased research and development and selling, general and administrative expenses in future periods to support RYTELO's U.S. commercialization, further development in other indications (IMpactMF, IMproveMF, IMpress trials), and preparations for EU commercialization in 2026. Interest expense is also expected to rise due to existing and potential future debt drawdowns. The interim analysis for Overall Survival (OS) in the IMpactMF trial is expected in the second half of 2026, with final analysis in the second half of 2028. The company believes its existing cash and anticipated RYTELO revenues will fund operations for the foreseeable future, but acknowledges the need for additional funding if sales targets are not met or unforeseen events occur.

Management Comments

• Our priority is to drive new patient starts across the breadth of the eligible patient population in RYTELO's approved indication in the U.S.
• Our strategy to drive sales growth in the U.S. is currently focused on three key areas: investing additional resources to increase brand awareness; refining our marketing and medical efforts to enhance prescribing clarity and confidence with the approved use of RYTELO; and implementing programs to expand key opinion leader support and advocacy.
• We believe that our existing cash, cash equivalents, and marketable securities, together with anticipated net revenues from U.S. sales of RYTELO, will be sufficient to fund our projected operating requirements for the foreseeable future.

Industry Context

Geron Corporation operates in the highly competitive biopharmaceutical industry, specifically targeting hematologic malignancies. RYTELO, a first-in-class telomerase inhibitor, represents a novel mechanism of action in a market with high unmet needs, particularly in lower-risk Myelodysplastic Syndromes (MDS). The company aims to differentiate RYTELO through its potential disease-modifying activity and benefits in difficult-to-treat patient sub-populations. The planned commercialization in the EU and ongoing Phase 3 trial in myelofibrosis (MF) position Geron to expand its presence in the myeloid hematologic malignancy space, competing with established pharmaceutical companies and emerging biotechnologies.

Management Changes

Corporate Governance

Legal Proceedings

• Two putative securities class action lawsuits, Dabestani v. Geron Corporation, et al. and Potvin v. Geron Corporation, et al., filed in March 2025, consolidated into In re Geron Corporation Securities Litigation. Allegations include materially false and misleading statements concerning RYTELO's commercial potential, lack of healthcare provider awareness, monitoring burdens, and impacts of seasonality and competition. A motion to dismiss was filed on October 7, 2025.
• Three purported stockholder derivative complaints, Bishop v. Scarlett, et al., Lerner v. Scarlett, et al., and Willis v. Scarlett, et al., filed in April 2025, consolidated into In re Geron Corporation Derivative Litigation. These allege breach of fiduciary duties and federal securities law violations by current and former directors and officers, based on similar allegations as the securities class actions. This action was stayed on June 17, 2025, pending the outcome of the motion to dismiss in the Securities Class Action.
• A purported stockholder made a demand on the board of directors on August 29, 2025, to commence a civil action against current and former directors for similar allegations. The board deferred a final decision on September 19, 2025. On October 7, 2025, the purported stockholder filed a derivative suit, Jae Hyung v. Bir, et al., with similar allegations.

Stakeholder Impact

• Shareholders: Potential for dilution from future equity capital raises, impact of stock price volatility due to market conditions and litigation, and potential for substantial damages or settlements from ongoing lawsuits.
• Employees: Changes in executive leadership, potential for increased personnel costs to attract and retain talent, and challenges related to managing a remote workforce across multiple jurisdictions.
• Customers (Patients/Healthcare Providers): Continued availability of RYTELO, potential for new indications, but also risks related to product safety, efficacy, pricing, and reimbursement policies.
• Suppliers/Creditors: Reliance on third-party manufacturers for RYTELO supply, exposure to credit risk from financial institutions, and obligations under the Pharmakon Loan Agreement and Royalty Pharma Agreement.
• Regulatory Authorities: Ongoing scrutiny of RYTELO's post-marketing requirements, clinical trial conduct, and compliance with healthcare laws.

Next Steps

• Continue to drive new patient starts across the eligible patient population for RYTELO in the U.S.
• Refine marketing and medical efforts to enhance prescribing clarity and confidence for RYTELO.
• Implement programs to expand key opinion leader support and advocacy for RYTELO.
• Prepare for planned commercialization of RYTELO in select EU markets in 2026, including reimbursement, Health Technology Assessment (HTA) submissions, market access, and distribution.
• Work with experienced third parties for commercialization and marketing of RYTELO in the EU.
• Continue the Phase 3 IMpactMF clinical trial for relapsed/refractory myelofibrosis, with interim analysis for OS expected in H2 2026 and final analysis in H2 2028.
• Continue ongoing Phase 1 IMproveMF combination clinical trial in frontline MF and Phase 2 investigator-led IMpress clinical trial in higher-risk MDS and acute myeloid leukemia.
• Remediate the material weakness in internal control over financial reporting related to ITGCs by the end of the fourth quarter of 2025.
• Vigorously defend against the pending securities class action and derivative lawsuits.

Key Dates

Recommendation

Geron Corporation presents a mixed financial and operational picture. While RYTELO's initial commercial launch shows promising revenue growth and the IMpactMF Phase 3 trial is fully enrolled, indicating strong pipeline progress, the company continues to operate at a significant net loss and is burning cash. The identified material weakness in internal controls and the ongoing securities litigation introduce considerable uncertainty and potential financial liabilities. Given the high volatility inherent in commercial-stage biopharmaceutical companies, coupled with these specific challenges and opportunities, a 'Hold' recommendation is prudent. Investors should await further clarity on RYTELO's sustained commercial success, the resolution of legal proceedings, and the effective remediation of internal control issues before making more aggressive investment decisions.

Keywords

RYTELO, imetelstat, myelodysplastic syndromes, MDS, myelofibrosis, MF, blood cancer, biopharmaceutical, oncology, telomerase inhibitor, SEC filing, GERN, clinical trial, FDA approval, EU marketing authorization, financial results, commercialization, drug development, corporate governance, litigation